CMS Approves Transitional Pass-Through Payment

The company announced that the Centre for Medicare/Medicaid (CMS) has approved a new reimbursement code that will provide separate payment for Recell devices used in the outpatient setting. The Transitional Pass-Through Payment (TPT) is expect to reimburse hospitals for approximately US$6,200 related to the use of the device. The event represents an important breakthrough for the company and further validation of the clinical benefit of the Recell technology. TPT’s are reserved for devices that offer substantial clinical improvement over the standard of care and are made available where the cost of the device would otherwise represent an obstacle to patient benefit.

The TPT comes into effect from 1 January 2022. The company plans a launch amongst a small number of existing hospital clients to ensure commercial payers follow suite with the CMS. A larger scale roll out will follow in the back half of CY22 (1H FY23) to specialist burns hospitals. The serviceable market in burns is estimated at US$260m of which small burns with total body surface area is in the range of 5-10% comprises ~US$60m. The TPT will be appropriate for treatment of these wounds.

Today’s announcement had been foreshadowed in numerous company updates and represents the first in a series of high profile news flow. Recell is expected to gain a broad label approval from the Japanese PMDA this quarter that may include Vitiligo in addition to burns, trauma and pediatric use. In the clinic the company expects to enroll the final patient in the Vitiligo trial this quarter. Initial proof of concept data is also expected in Epidermolysis Bullosa and facial rejuvenation.

Investment View: Maintain Buy Rating, Price Target $9.80

1Q22 results are due next week. Guidance is for commercial revenues of US$7m relative to US$6.8m from 4Q21. FY22/FY23 revenues are upgraded by 5% and 12% respectively related to the TPT code. The FY22 EBIT loss is reduced by ~$8m to ($22.4m) largely attributable to the rationalisation of the expected scrip based remuneration which has now been adjusted to be more consistent with the prior year charge. We maintain our Buy rating and price target of $9.80.

To read the full report click the read more button below.

View Detailed Report
Authored by John Hester – Analyst – at Bell Potter Securities, 4 November 2021
Important Disclaimer—This may affect your legal rights: Because this document has been prepared without consideration of any specific client’s financial situation, particular needs and investment objectives, a Bell Potter Securities Limited investment adviser (or the financial services licensee, or the proper authority of such licensee, who has provided you with this report by arrangement with Bell Potter Securities Limited) should be consulted before any investment decision is made. While this document is based on the information from sources which are considered reliable, Bell Potter Securities Limited, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. Nor does Bell Potter Securities Limited accept any responsibility to inform you of any matter that subsequently comes to its notice, which may affect any of the information contained in this document. This document is a private communication to clients and is not intended for public circulation or for the use of any third party, without the prior approval of Bell Potter Securities Limited. In the USA and the UK this research is only for institutional investors. It is not for release, publication or distribution in whole or in part to any persons in the two specified countries. This is general investment advice only and does not constitute advice to any person.
Disclosure of Interest: Bell Potter Securities Limited receives commission from dealing in securities and its authorised representatives, or introducers of business, may directly share in this commission. Bell Potter Securities and its associates may hold shares in the companies recommended.